Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1

Status

Active not recruiting 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2Thoracic 1Other solid neoplasm 1Endocrine 1Dermatologic 1

Conditions

Colorectal Neoplasms 55Ovarian Neoplasms 39Carcinoma, Hepatocellular 39Neoplasms 25Fallopian Tube Neoplasms 21Carcinoma, Non-Small-Cell Lung 20Endometrial Neoplasms 14Glioblastoma 11Breast Neoplasms 11Brain Neoplasms 11Colonic Neoplasms 10Neoplasm Metastasis 9Lung Neoplasms 8Liver Neoplasms 8Uterine Cervical Neoplasms 7Stomach Neoplasms 6Rectal Neoplasms 6Glioma 6Biliary Tract Neoplasms 6Carcinoma, Ovarian Epithelial 5Triple Negative Breast Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Parkinson Disease 4, Autosomal Dominant Lewy Body 4Small Cell Lung Carcinoma 3Sarcoma 3Recurrence 3Peritoneal Neoplasms 3Pancreatic Neoplasms 3Neoplasms, Nerve Tissue 3Gastrointestinal Neoplasms 3

Interventions

Cisplatin 18Gemcitabine 14Radiotherapy, Intensity-Modulated 11Magnetic Resonance Spectroscopy 8toripalimab 7Specimen Handling 7Capecitabine 7Platinum 5Drug Therapy 51,2-diaminocyclohexaneplatinum II citrate 5camrelizumab 4Radiotherapy 4Nivolumab 4spartalizumab 3sintilimab 3anlotinib 3Immunoglobulin G 3Immune Checkpoint Inhibitors 3Docetaxel 3Disulfides 3atezolizumab 2Radiation 2Phantoms, Imaging 2Ipilimumab 2Carboplatin 2CTLA-4 Antigen 2Biopsy 2Bevacizumab 218-O-demethylcervinomycin A2 2tislelizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Nasopharyngeal Carcinoma × Bevacizumab × 90 days × Clear all
NCT05063552 2026-06-03

Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers

National Cancer Institute (NCI)

Phase 2/3 Active not recruiting
430 enrolled
Head & Neck

Lymphoid Interstitial Pneumonia, Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT03074513 2026-03-11

Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
133 enrolled
DermatologicEndocrineHead & NeckOther solid neoplasmThoracic

Nasopharyngeal Carcinoma, Mesothelioma, Malignant, Adenocarcinoma, Mucinous, Adenoma, Islet Cell, Nasopharyngeal Neoplasms, Carcinoma, Merkel Cell, Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon âš¡